- Home
- KYNB vs ABVC Comparison
KYNB vs ABVC Comparison
Compare KYNB & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | ABVC |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 34.6M |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | KYNB | ABVC |
|---|---|---|
| Price | $7.87 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.1K | ★ 94.7K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9552.08 | 7.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,440,000.00 | $509,589.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $0.71 |
| 52 Week High | $9.58 | $3.39 |
Technical Indicators
Market Signals| Indicator | KYNB | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 56.47 |
| Support Level | $7.40 | $0.96 |
| Resistance Level | $7.95 | $1.14 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 45.43 | 89.06 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.